- Home
- TVGN
as of 08-21-2026 11:44am EST
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | 21.3M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 9.1K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.16 | EPS Growth: | -11442.86 |
| 52 Week Low/High: | $0.14 - $12.03 | Next Earning Date: | 05-13-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -2.02 | Index: | N/A |
| Free Cash Flow: | -12393016.0 | FCF Growth: | N/A |
Earnings Transcripts
SEC 8-K filings with transcript text
2024 Q1 Q1 2024 Earnings
8-K Apr 26, 2024
Q1 2024 Earnings
8-KApr 26, 2024
Compare TVGN vs Leading Stocks
See how TVGN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TVGN Tevogen Bio Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.